[8-K] Dermata Therapeutics, Inc. Warrant Reports Material Event

Rhea-AI Filing Summary

On August 13, 2025 Dermata Therapeutics, Inc. submitted a Current Report on Form 8-K to furnish a press release that provides a corporate update and reports second quarter 2025 financial results for the quarter ended June 30, 2025. The filing identifies the press release as Exhibit 99.1 and an Interactive XBRL cover page as Exhibit 104. The company states the information in Item 2.02 and Exhibit 99.1 is furnished, not "filed," and therefore is not subject to Section 18 liability or automatically incorporated by reference into future filings. The report is signed by CEO Gerald T. Proehl.

Positive

• Timely public disclosure of second quarter 2025 results via an Exhibit 99.1 press release and an iXBRL cover page (Exhibit 104).
• Regulation FD compliance indicated by furnishing a press release under Item 2.02 and referencing the same disclosure in Item 7.01.

Negative

• Furnished, not filed: the company expressly states Exhibit 99.1 is furnished and not subject to Section 18 liability and will not be automatically incorporated by reference into future filings.

Insights

Financial Analyst

TL;DR: The 8-K furnishes Dermata's Q2 2025 results via a press release; investors must review Exhibit 99.1 for the actual numbers.

The filing itself does not reproduce financial line items within the 8-K text; instead it furnishes a press release (Exhibit 99.1) reporting results for the quarter ended June 30, 2025 and provides an iXBRL cover page (Exhibit 104). That approach delivers timely disclosure under Regulation FD but requires readers to consult the attached press release and iXBRL for detailed revenue, expense, and EPS figures. Because the company explicitly states the material is "furnished, not filed," standard Section 18 liability protections do not apply to the content of Exhibit 99.1.

Corporate Governance Expert

TL;DR: Routine Reg FD-compliant disclosure; the company clarifies that the press release is furnished, limiting incorporation and Section 18 exposure.

The 8-K follows a common governance practice of furnishing a corporate update and quarterly results by exhibit rather than filing them into the formal record. Item 2.02 and Item 7.01 cross-reference the same press release, and Item 9.01 lists Exhibits 99.1 and 104. The registrant's signature by CEO Gerald T. Proehl indicates corporate authorization of the disclosure. Investors and auditors should note the filing-level distinction between "furnished" versus "filed" material when relying on the content for formal disclosure or incorporation by reference.

false 0001853816 0001853816 2025-08-13 2025-08-13 0001853816 DRMA:CommonStockParValue0.0001PerShareMember 2025-08-13 2025-08-13 0001853816 DRMA:WarrantsExercisableForOneShareOfCommonStockMember 2025-08-13 2025-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

Dermata Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40739		86-3218736
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

3525 Del Mar Heights Rd., #322 San Diego, CA		92130
(Address of principal executive offices)		(Zip Code)

(858) 800-2543

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class:		Trading Symbol		Name of Each Exchange on which Registered
Common Stock, par value $0.0001 per share		DRMA		The Nasdaq Capital Market
Warrants, exercisable for one share of Common Stock		DRMAW		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 2.02. Results of Operations and Financial Condition.

On August 13, 2025, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the quarter ended June 30, 2025. A copy of the press release is furnished under Item 2.02 as Exhibit 99.1.

The information included in this Item 2.02 and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act made after the date hereof, the information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 7.01. Regulation FD Disclosure.

See “Item 2.02 Results of Operations and Financial Condition” above.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated August 13, 2025, issued by Dermata Therapeutics, Inc. entitled “Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results.”
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	DERMATA THERAPEUTICS, INC.
Dated: August 13, 2025	By:	/s/ Gerald T. Proehl
		Gerald T. Proehl
		Chief Executive Officer

FAQ

What did Dermata (DRMAW) file in this 8-K?

The company furnished a press release providing a corporate update and reporting second quarter 2025 financial results for the quarter ended June 30, 2025 (Exhibit 99.1) and included an Interactive XBRL cover page (Exhibit 104).

Is the press release in the 8-K considered "filed" under the Exchange Act?

No. The filing states the information in Item 2.02 and Exhibit 99.1 is "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.

Does the Form 8-K include the financial statement line items in the body of the filing?

No financial line items are reproduced in the 8-K text. The filing furnishes a press release (Exhibit 99.1) reporting results for the quarter ended June 30, 2025; readers should consult Exhibit 99.1 and the iXBRL exhibit for detailed figures.

What exhibits are attached to this 8-K?

Exhibit 99.1 (press release dated August 13, 2025) and Exhibit 104 (Cover Page Interactive Data File embedded within the Inline XBRL document).

Who signed the 8-K for Dermata Therapeutics?

Gerald T. Proehl, Chief Executive Officer, signed the report on behalf of the registrant.